June 25, 2018
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies.
Among the studies highlighted by the association was an...
December 18, 2017
Milpitas, California-based diabetes management device maker Bigfoot Biomedical has raised $37 million in Series B funding in a round co-led by funds from Janus Henderson Investors and Quadrant Capital Advisors. Additional participants included Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange.
December 8, 2017
Heads of the FDA’s Center for Devices and Radiological Health (CDRH) recently penned a blog post describing their previous and ongoing efforts with closed-loop artificial pancreas manufacturers to ensure proper testing and validation of the devices.
In it, Courtney Lias, director of the Division of Chemistry and Toxicology Devices at CDRH, and Stayce Beck, chief of the Diabetes Diagnostics...
December 8, 2017
Indianapolis-based pharmaceutical Eli Lilly and Company announced this week that the first Type 1 diabetes patient has been dosed in a feasibility study of the company’s investigational Automated Insulin Delivery (AID) system.
The company’s hybrid closed-loop platform consists of an insulin pump with a dedicated controller for system inputs, a dosing algorithm, and a continuous glucose monitor (...
October 18, 2017
Efforts to build artificial pancreas (AP) systems under open protocols will get a boost from JDRF, a multinational group that funds Type 1 diabetes research and other programs. The organization has announced a new initiative to not only provide funds for these DIY and frequently reverse engineered projects, but will also provide the regulatory and liability guidance necessary for a public release...
January 30, 2017
Milpitas, California-based Bigfoot Biomedical, a diabetes management company working on their first product, announced an investment from the Juvenile Diabetes Research Foundation (JDRF)’s newly launched venture fund, T1D, focused on early stage companies working on type 1 diabetes. The terms of the investment were not disclosed, but Bigfoot previously raised $35.5 million.
The funding will be...
October 6, 2016
Boston-based nonprofit T1D Exchange has announced its intentions to make a multi-million dollar investment in automated insulin delivery technologies, the smart algorithms that serve as the bridge between CGMs and insulin pumps in the quest to create an artificial pancreas.
“Type 1 diabetes is a disease that, since the invention of artificial insulin back in 1921, still plagues us because...